10-Q: Phio Pharmaceuticals Reports Q1 2025 Results, Highlights Progress in Clinical Trial

Phio Pharmaceuticals reports its Q1 2025 financial results and provides an update on its ongoing clinical trial for PH-762.

Summary

• Phio Pharmaceuticals Corp., a clinical-stage biopharmaceutical company, has released its financial results for the quarter ended March 31, 2025.
• The company is focused on developing immuno-oncology therapeutics using its proprietary INTASYL technology.
• Phio is currently conducting a Phase 1b clinical trial for PH-762, an INTASYL compound designed to reduce the expression of PD-1, for the treatment of cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma.
• Ten patients have been treated in Cohorts 1, 2, and 3 of the clinical trial, with 4 out of 9 patients with cutaneous squamous cell carcinoma (cSCC) achieving a pathologic complete response (100% tumor clearance) at Day 36.
• The fourth cohort is currently enrolling patients, and the company expects to complete enrollment in the trial in the third quarter of 2025.
• The company terminated its Clinical Co-Development Agreement with AgonOx in May 2024.
• The net loss for the three months ended March 31, 2025, was $(1.769) million, compared to a net loss of $(2.154) million for the same period in 2024.
• As of March 31, 2025, Phio had cash and cash equivalents of $13.278 million, which the company believes will fund operations into the second quarter of 2026.
• The company raised approximately $6.7 million in net proceeds from January 2025 financings.
• Phio expects to continue incurring substantial operating losses for the next several years as it continues to develop its product candidates.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While the company shows progress in its clinical trial and has improved its financial position, it still faces significant risks and uncertainties, particularly regarding its ability to secure future funding.

Positives

• The Phase 1b clinical trial for PH-762 is showing promising early results, with a high rate of complete responses in cSCC patients.
• The company has sufficient cash and cash equivalents to fund operations into the second quarter of 2026.
• The net loss for Q1 2025 decreased compared to Q1 2024.
• The company successfully raised additional capital through recent financings.

Negatives

• The company has a history of recurring losses from operations and expects to continue to incur substantial operating losses for the foreseeable future.
• Phio has not yet received product revenues.
• The company's ability to continue as a going concern is dependent on raising additional capital.
• The company terminated its Clinical Co-Development Agreement with AgonOx in May 2024.

Risks

• The success of the company is dependent on the success of its INTASYL technology and product candidates, which are unproven.
• The company's product candidates are in an early stage of development and may fail or experience significant delays.
• The company relies on third parties for the manufacture of clinical supply for its product candidates.
• The company will require substantial additional funds to complete its research and development activities.
• The company may not be able to remain compliant with the continued listing requirements of The Nasdaq Capital Market.
• Changes in U.S. and international trade policies may adversely impact the company's business and operating results.

Future Outlook

The company expects that its cash and cash equivalents will enable it to fund its current operating plan into the second quarter of 2026 and expects to continue to incur substantial additional operating losses for at least the next several years as it continues to develop its product candidates and seek marketing approval.

Industry Context

Phio Pharmaceuticals is operating in the competitive immuno-oncology space, where companies are developing novel therapies to harness the body's immune system to fight cancer. The company's INTASYL technology represents a unique approach to targeting specific proteins that reduce the body's ability to fight cancer.

Comparison to Industry Standards

• Phio Pharmaceuticals' focus on intratumoral injection of PH-762 aligns with the industry trend of exploring localized cancer therapies to minimize systemic side effects, similar to approaches being investigated by companies like Replimune with their oncolytic virus RP1.
• The reported pathologic complete response rate of 44% (4 out of 9 patients) in cSCC patients treated with PH-762 is a promising early signal, but needs to be compared to benchmark data from standard-of-care treatments like surgery or radiation, as well as other investigational therapies in similar patient populations.
• The company's cash runway into the second quarter of 2026 provides a degree of financial stability, but it's crucial to monitor their burn rate and compare it to peers like BioNTech or Moderna, who have significantly larger cash reserves due to commercialized products.
• Phio's decision to defer the IND submission for PH-894 to focus on PH-762 reflects a common strategy among smaller biotech companies to prioritize their lead asset, but it also introduces the risk of pipeline stagnation if PH-762 fails to meet expectations.

Stakeholder Impact

• Shareholders: The company's financial performance and clinical trial results will directly impact shareholder value.
• Employees: The company's ability to secure funding will impact job security and future opportunities.
• Patients: The success of the clinical trial could lead to new treatment options for cancer patients.
• Investors: The company's ability to raise capital will impact the company's ability to continue operations.

Next Steps

• Continue enrollment in the Phase 1b clinical trial for PH-762, with expected completion in the third quarter of 2025.
• Assess cash and cash equivalents and future funding requirements.
• Seek additional funding to sustain future operations.
• Monitor compliance with Nasdaq Listing Rules.

Key Dates

Keywords

PH-762, INTASYL, clinical trial, immuno-oncology, biopharmaceutical, financing, PD-1, cancer, Phio Pharmaceuticals